{"ok":true,"trend":{"id":236678,"platform":"news","region":"global","key":"alx oncology announces nature medicine publication of aspen-06 phase 2 clinical data demonstrating strong responses and durable clinical benefit with evorpacept in her2-positive gastric cancer","title":"ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer","url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPNmhydTF4ZDBNOXRuQV9QVDk0VTF1TjA4ajN3akpybG9iTXFwRzZjOVl0WnNVc1VlMU1oY3E0emJOdHN0aElMN2ZnRlNMb1JwZEk2RDdCWGJHRkNvTG5mSzlpZFk2QWZHMHBZMFJobHYzWE40V3pwOGVqY1BLWFltQTVEY3hFYklfY3dvcnk5MHI?oc=5","first_seen":"2026-09-28T13:16:46.462788Z","last_seen":"2026-09-28T14:41:11.897021Z","last_rank":22,"peak_rank":17,"last_volume":null,"peak_volume":0,"seen_count":2,"score":0.956875,"category_hint":"medicine","section":"health","category":"medicine","summary":"ALX Oncology announced that Nature Medicine has published Phase 2 results from its ASPEN-06 trial, showing strong responses and durable clinical benefit with evorpacept combined with trastuzumab and chemotherapy in patients with HER2-positive gastric cancer. The publication adds peer-reviewed weight to the company's lead drug candidate and supports its ongoing development program in gastroesophageal cancers.","why":"Investors and oncology specialists are following clinical progress for ALX Oncology's lead asset evorpacept.","tone":"positive","entities":["ALX Oncology","Evorpacept","Nature Medicine","ASPEN-06 trial"],"summarized_at":"2026-09-28T13:18:25.956363Z","meta":{"via":"scan","lang":"en","term":"medicine","source":"uk.finance.yahoo.com","generic":0.03,"published":"Mon, 28 Sep 2026 12:00:00 GMT"},"nw":0.47,"promo":0.06,"kind":"news_event","importance":1.59,"hidden":false,"hide_reason":null,"judged_at":"2026-09-28T13:16:58.641470Z","title_en":"ALX Oncology publishes promising evorpacept gastric cancer trial data in Nature Medicine","section_name":"Health","category_name":"Medicine","timeline":[{"captured_at":"2026-09-28T13:16:46.462788Z","rank":17,"volume":null},{"captured_at":"2026-09-28T14:41:11.897021Z","rank":22,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPNmhydTF4ZDBNOXRuQV9QVDk0VTF1TjA4ajN3akpybG9iTXFwRzZjOVl0WnNVc1VlMU1oY3E0emJOdHN0aElMN2ZnRlNMb1JwZEk2RDdCWGJHRkNvTG5mSzlpZFk2QWZHMHBZMFJobHYzWE40V3pwOGVqY1BLWFltQTVEY3hFYklfY3dvcnk5MHI?oc=5","author":"Yahoo Finance UK","title":"ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer","snippet":null,"posted_at":"2026-09-28T12:00:00Z","likes":null}],"elsewhere":[],"window":"7d"}}